Tesamorelin Explained: Growth-Hormone Signalling and Visceral Fat

Peptide Library

Tesamorelin is a peptide medicine connected to growth-hormone signalling. Its best-established clinical use is much more specific than broad claims about belly fat or general weight loss.

What is tesamorelin?

Tesamorelin is an analogue of growth hormone-releasing factor, also called GHRF. It stimulates the release of the body’s own growth hormone and can increase insulin-like growth factor-1, or IGF-1. It is therefore different from administering growth hormone directly and different from GLP-1 receptor medicines. [1][3]

What is its authorised use?

The US Egrifta WR label authorises reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It explicitly states that the medicine is not indicated for weight-loss management and that long-term cardiovascular safety has not been established. This is a US product-specific indication, not a claim that every tesamorelin-labelled product is approved in South Africa. [1]

What does the clinical research show?

A randomised study in adults with HIV and central fat accumulation examined visceral adipose tissue: fat inside the abdomen, around internal organs. The study reported reductions in this compartment, with no corresponding reduction in abdominal subcutaneous or limb fat. Benefits were lost after participants switched to placebo. Those findings illustrate why a result in one fat compartment and population should not become a claim about universal fat loss. [2]

Why does monitoring matter?

The Egrifta WR information describes concerns involving elevated IGF-1, fluid retention, glucose intolerance and hypersensitivity. Active malignancy is a contraindication. The label also distinguishes Egrifta WR from Egrifta SV: their formulations and preparation instructions differ and they are not substitutable. The actual prescribed product therefore matters to both interpretation and use. [1][3]

How to assess a visceral-fat claim

Look for the population studied, how fat was measured and whether the claim concerns visceral fat, subcutaneous fat or total body weight. A change in waist appearance is not by itself proof of a measured change in visceral adipose tissue. Tesamorelin is best explained through its specific evidence and indication rather than a general “fat-burning” description.

Frequently asked questions

Is tesamorelin a general weight-loss medicine?

The cited US Egrifta WR label specifically says it is not indicated for weight-loss management.

Is visceral fat the same as fat under the skin?

No. Visceral fat is inside the abdominal cavity; subcutaneous fat is beneath the skin.

Are all tesamorelin preparations equivalent?

No. Formulations and authorised product instructions can differ.

Explore related articles

Sources

  1. FDA: Egrifta WR prescribing information
  2. Falutz et al., 2010: randomised tesamorelin trial in HIV-associated abdominal fat accumulation
  3. DailyMed: Egrifta WR warnings and precautions

Research checked: 11 October 2026. Educational information; not a diagnosis, prescription or dosing guide. Prepared for SkyCor with AI-assisted research and drafting; not independently medically reviewed. Approval information relates to the named products and jurisdictions, not every product carrying the same ingredient name.

Author